First Time Loading...

ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.08 AUD Market Closed
Updated: May 8, 2024

Intrinsic Value

IPD's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. [ Read More ]

The intrinsic value of one IPD stock under the Base Case scenario is 0.05 AUD. Compared to the current market price of 0.08 AUD, ImpediMed Ltd is Overvalued by 41%.

Key Points:
IPD Intrinsic Value
Base Case
0.05 AUD
Overvaluation 41%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ImpediMed Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IPD stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
ImpediMed Ltd

Provide an overview of the primary business activities
of ImpediMed Ltd.

What unique competitive advantages
does ImpediMed Ltd hold over its rivals?

What risks and challenges
does ImpediMed Ltd face in the near future?

Summarize the latest earnings call
of ImpediMed Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ImpediMed Ltd.

Provide P/S
for ImpediMed Ltd.

Provide P/E
for ImpediMed Ltd.

Provide P/OCF
for ImpediMed Ltd.

Provide P/FCFE
for ImpediMed Ltd.

Provide P/B
for ImpediMed Ltd.

Provide EV/S
for ImpediMed Ltd.

Provide EV/GP
for ImpediMed Ltd.

Provide EV/EBITDA
for ImpediMed Ltd.

Provide EV/EBIT
for ImpediMed Ltd.

Provide EV/OCF
for ImpediMed Ltd.

Provide EV/FCFF
for ImpediMed Ltd.

Provide EV/IC
for ImpediMed Ltd.

Show me price targets
for ImpediMed Ltd made by professional analysts.

What are the Revenue projections
for ImpediMed Ltd?

How accurate were the past Revenue estimates
for ImpediMed Ltd?

What are the Net Income projections
for ImpediMed Ltd?

How accurate were the past Net Income estimates
for ImpediMed Ltd?

What are the EPS projections
for ImpediMed Ltd?

How accurate were the past EPS estimates
for ImpediMed Ltd?

What are the EBIT projections
for ImpediMed Ltd?

How accurate were the past EBIT estimates
for ImpediMed Ltd?

Compare the revenue forecasts
for ImpediMed Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ImpediMed Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ImpediMed Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of ImpediMed Ltd compared to its peers.

Compare the P/E ratios
of ImpediMed Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing ImpediMed Ltd with its peers.

Analyze the financial leverage
of ImpediMed Ltd compared to its main competitors.

Show all profitability ratios
for ImpediMed Ltd.

Provide ROE
for ImpediMed Ltd.

Provide ROA
for ImpediMed Ltd.

Provide ROIC
for ImpediMed Ltd.

Provide ROCE
for ImpediMed Ltd.

Provide Gross Margin
for ImpediMed Ltd.

Provide Operating Margin
for ImpediMed Ltd.

Provide Net Margin
for ImpediMed Ltd.

Provide FCF Margin
for ImpediMed Ltd.

Show all solvency ratios
for ImpediMed Ltd.

Provide D/E Ratio
for ImpediMed Ltd.

Provide D/A Ratio
for ImpediMed Ltd.

Provide Interest Coverage Ratio
for ImpediMed Ltd.

Provide Altman Z-Score Ratio
for ImpediMed Ltd.

Provide Quick Ratio
for ImpediMed Ltd.

Provide Current Ratio
for ImpediMed Ltd.

Provide Cash Ratio
for ImpediMed Ltd.

What is the historical Revenue growth
over the last 5 years for ImpediMed Ltd?

What is the historical Net Income growth
over the last 5 years for ImpediMed Ltd?

What is the current Free Cash Flow
of ImpediMed Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for ImpediMed Ltd.

Financials

Balance Sheet Decomposition
ImpediMed Ltd

Current Assets 41.5m
Cash & Short-Term Investments 36.9m
Receivables 2.7m
Other Current Assets 1.9m
Non-Current Assets 17.1m
Long-Term Investments 48k
PP&E 1.7m
Intangibles 15.4m
Current Liabilities 5.9m
Accounts Payable 2.5m
Other Current Liabilities 3.4m
Non-Current Liabilities 1.7m
Long-Term Debt 963k
Other Non-Current Liabilities 712k
Efficiency

Earnings Waterfall
ImpediMed Ltd

Revenue
10.5m AUD
Cost of Revenue
-1.4m AUD
Gross Profit
9.1m AUD
Operating Expenses
-29.8m AUD
Operating Income
-20.7m AUD
Other Expenses
1.3m AUD
Net Income
-19.4m AUD

Free Cash Flow Analysis
ImpediMed Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

IPD Profitability Score
Profitability Due Diligence

ImpediMed Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
ROIC is Increasing
32/100
Profitability
Score

ImpediMed Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

IPD Solvency Score
Solvency Due Diligence

ImpediMed Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

ImpediMed Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPD Price Targets Summary
ImpediMed Ltd

Wall Street analysts forecast IPD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPD is 0.18 AUD with a low forecast of 0.14 AUD and a high forecast of 0.21 AUD.

Lowest
Price Target
0.14 AUD
77% Upside
Average
Price Target
0.18 AUD
123% Upside
Highest
Price Target
0.21 AUD
163% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

IPD Price
ImpediMed Ltd

1M 1M
-10%
6M 6M
-43%
1Y 1Y
-52%
3Y 3Y
-36%
5Y 5Y
-60%
10Y 10Y
-57%
Annual Price Range
0.08
52w Low
0.077
52w High
0.23
Price Metrics
Average Annual Return -14.61%
Standard Deviation of Annual Returns 40.76%
Max Drawdown -85%
Shares Statistics
Market Capitalization 161.9m AUD
Shares Outstanding 1 997 847 100
Percentage of Shares Shorted
N/A

IPD Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

ImpediMed Ltd Logo
ImpediMed Ltd

Country

Australia

Industry

Health Care

Market Cap

161.9m AUD

Dividend Yield

0%

Description

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

Contact

QUEENSLAND
Brisbane
Pinkenba, U 1 50 Parker Ct
+61738603700.0
https://www.impedimed.com

IPO

2007-10-24

Employees

73

Officers

Chief Operating Officer
Mr. Shashi Tripathi
MD, Interim CEO & Director
Dr. Parmjot Bains M.D.
Interim CFO & Executive Director
Mr. McGregor Grant BEc, C.A., FCIS, GAICD
Senior Vice President of R&D and Technology
Mr. Dennis Schlaht
Vice President of Sales
Lisa Prom
Chief Strategy Officer
Ms. Joann Yao
Show More
Chief Medical Center
Dr. Steven Chen M.B.A., M.D.
Company Secretary
Ms. Leanne Ralph AAICD, ACIS, BBus
Medical Director
Dr. Walton A. Taylor
Show Less

See Also

Discover More
What is the Intrinsic Value of one IPD stock?

The intrinsic value of one IPD stock under the Base Case scenario is 0.05 AUD.

Is IPD stock undervalued or overvalued?

Compared to the current market price of 0.08 AUD, ImpediMed Ltd is Overvalued by 41%.